SEC Filing Summary: Nephros, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nephros, Inc. on November 14, 2006. The report addresses a notice received from the American Stock Exchange (AMEX) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it explicitly states the Company is non-compliant with AMEX standards due to:
- Shareholders' equity of less than $2,000,000, $4,000,000, and $6,000,000 thresholds.
- Losses from continuing operations and/or net losses in two of the three most recent fiscal years, three of the four most recent fiscal years, and five of the most recent fiscal years.
Material Changes and Listing Status
On November 14, 2006, the AMEX staff reviewed the Company's plan of compliance and agreed to continue the Company's listing. The Company has been granted a compliance period ending January 17, 2008, to regain compliance with the AMEX Company Guide Section 1003 standards.
Outlook, Risks, and Contingencies
Compliance Requirements: During the plan period, the Company must provide periodic updates to the AMEX staff regarding its compliance initiatives and is subject to periodic review.
Delisting Risk: If the Company fails to meet the continued listing standards by January 17, 2008, or fails to make progress consistent with its plan, the AMEX may initiate immediate delisting proceedings.
Investor Verification Checklist
- Verify the specific details of the Company's "plan of compliance" referenced in the filing.
- Confirm the Company's current shareholders' equity and net loss figures from the most recent 10-K or 10-Q filings to assess the severity of the deficit.
- Monitor future 8-K filings for updates on compliance progress before the January 17, 2008 deadline.
- Review the attached press release (Exhibit 99.1) for management's specific strategy to address the equity and profitability deficiencies.